By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a




Company News
TapImmune (TPIV) Provides Year End 2016 Corporate and Clinical Update 3/15/2017 10:04:44 AM
TapImmune (TPIV) Announces Fully Funded Phase II Clinical Study Of HER2-Targeted Vaccine In Early Breast Cancer 3/14/2017 8:24:51 AM
TapImmune (TPIV) Advances TPIV 200 Phase II Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review 2/15/2017 7:45:09 AM
TapImmune (TPIV) Expands Intellectual Property On PolyStart Platform For Use In Next-Generation T-Cell Vaccines 2/7/2017 10:47:00 AM
TapImmune (TPIV) Completes Scale-Up And GMP Manufacturing Of TPIV 200 Vaccine To Supply Additional Phase 2 Clinical Trials 2/2/2017 9:54:09 AM
TapImmune (TPIV) Release: Pharma Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial 1/24/2017 7:27:07 AM
TapImmune (TPIV) Release: Pharma Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients 1/10/2017 7:53:06 AM
TapImmune (TPIV): Year End 2016 Update 1/3/2017 7:24:52 AM
TapImmune (TPIV) Commences Trading On The Nasdaq Capital Market 11/9/2016 12:50:24 PM
TapImmune (TPIV) Approved For Listing On The Nasdaq Capital Market 11/3/2016 8:26:37 AM